MXPA05012026A - Compuestos de azaindol como inhibidores de cinasa. - Google Patents

Compuestos de azaindol como inhibidores de cinasa.

Info

Publication number
MXPA05012026A
MXPA05012026A MXPA05012026A MXPA05012026A MXPA05012026A MX PA05012026 A MXPA05012026 A MX PA05012026A MX PA05012026 A MXPA05012026 A MX PA05012026A MX PA05012026 A MXPA05012026 A MX PA05012026A MX PA05012026 A MXPA05012026 A MX PA05012026A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
azaindole compounds
compounds
azaindole
methods
Prior art date
Application number
MXPA05012026A
Other languages
English (en)
Inventor
Peter Hansen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA05012026A publication Critical patent/MXPA05012026A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se relaciona con nuevos compuestos de azaindol que son inhibidores de cinasa, con metodos para su preparacion de intermediarios y composiciones farmaceuticas que los comprenden.
MXPA05012026A 2003-05-09 2004-05-06 Compuestos de azaindol como inhibidores de cinasa. MXPA05012026A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0301372A SE0301372D0 (sv) 2003-05-09 2003-05-09 Novel compounds
PCT/SE2004/000696 WO2004099205A1 (en) 2003-05-09 2004-05-06 Azaindole compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
MXPA05012026A true MXPA05012026A (es) 2006-02-03

Family

ID=20291270

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012026A MXPA05012026A (es) 2003-05-09 2004-05-06 Compuestos de azaindol como inhibidores de cinasa.

Country Status (13)

Country Link
US (1) US20060287354A1 (es)
EP (1) EP1625127B1 (es)
JP (1) JP2006525998A (es)
CN (1) CN1784403A (es)
AT (1) ATE362932T1 (es)
AU (1) AU2004236146B2 (es)
BR (1) BRPI0410117A (es)
CA (1) CA2523922A1 (es)
DE (1) DE602004006618T2 (es)
ES (1) ES2286634T3 (es)
MX (1) MXPA05012026A (es)
SE (1) SE0301372D0 (es)
WO (1) WO2004099205A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006114180A1 (de) 2005-04-25 2006-11-02 Merck Patent Gmbh Neuartige aza-heterozyklen als kinase-inhibitoren
MX2007014619A (es) * 2005-05-20 2009-02-13 Vertex Pharma Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
WO2007007919A2 (en) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
DK2348023T5 (da) * 2005-12-13 2017-05-15 Incyte Holdings Corp Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer
US20070208053A1 (en) * 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
WO2007118041A1 (en) * 2006-04-07 2007-10-18 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
CA2657247A1 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008039645A1 (en) 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
CA2673038C (en) 2006-12-22 2015-12-15 Incyte Corporation Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
MX2009007426A (es) * 2007-01-12 2009-07-17 Astellas Pharma Inc Compuesto de piridina condensado.
ES2431815T3 (es) 2007-04-11 2013-11-28 Kissei Pharmaceutical Co., Ltd. Derivado de (aza)indol y uso del mismo para fines médicos
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
EP2217565B1 (en) 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
BRPI0820544A2 (pt) 2007-11-16 2015-06-16 Incyte Corp 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
DK2288610T3 (en) 2008-03-11 2016-11-28 Incyte Holdings Corp Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
CA2730037A1 (en) 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
BRPI0919172A2 (pt) 2008-09-25 2015-12-15 Boehringer Ingelheim Int compostos os quais modulam seletivamente o receptor de cb2
EP2361902A4 (en) * 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
US8765727B2 (en) 2009-01-23 2014-07-01 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
CA2752150A1 (en) 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
AU2010249380B2 (en) 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2443107B1 (en) 2009-06-16 2018-08-08 Boehringer Ingelheim International GmbH Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
AR077465A1 (es) 2009-07-08 2011-08-31 Leo Pharma As Derivados de pirrolopirimidina como inhibidores de receptores jak y protein tirosin quinasas y uso farmaceutico de los mismos
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR101805936B1 (ko) 2009-10-09 2017-12-07 인사이트 홀딩스 코포레이션 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
WO2011109324A1 (en) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the cb2 receptor
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
MY178634A (en) 2010-05-21 2020-10-19 Incyte Corp Topical formulation for a jak inhibitor
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
US9233964B2 (en) 2011-01-07 2016-01-12 Leo Pharma A/S Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof
EP2675451B9 (en) 2011-02-18 2017-07-26 Novartis Pharma AG mTOR/JAK INHIBITOR COMBINATION THERAPY
EP2688890B1 (en) 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
IN2015DN02008A (es) 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
WO2014078486A1 (en) 2012-11-15 2014-05-22 Incyte Corporation Sustained-release dosage forms of ruxolitinib
KR102366356B1 (ko) 2013-03-06 2022-02-23 인사이트 홀딩스 코포레이션 Jak 저해제를 제조하기 위한 방법 및 중간생성물
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
PE20220579A1 (es) 2013-08-07 2022-04-20 Incyte Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1
KR101548492B1 (ko) 2013-09-23 2015-09-01 건국대학교 산학협력단 야누스 키나아제 1 (Janus kinase 1)의 활성을 선택적으로 저해하는 4-아미노-7-아자인돌-5-카르복사마이드 유도체
WO2015119126A1 (ja) * 2014-02-04 2015-08-13 大鵬薬品工業株式会社 アザインドール誘導体
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
WO2017091681A1 (en) 2015-11-24 2017-06-01 Aclaris Therapeutics, Inc. Selective kinase inhibitors
CN107513067A (zh) 2016-06-16 2017-12-26 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物
US10316038B2 (en) 2017-01-25 2019-06-11 Aclaris Therapeutics, Inc. Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
US10800775B2 (en) 2017-11-03 2020-10-13 Aclaris Therapeutics, Inc. Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
SG11202002947TA (en) 2017-11-03 2020-04-29 Aclaris Therapeutics Inc Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP4086245A1 (en) 2018-01-30 2022-11-09 Incyte Corporation Processes for preparing intermediates for the synthesis of a jak inhibitor
SG11202009441PA (en) 2018-03-30 2020-10-29 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
JP2021534244A (ja) 2018-08-10 2021-12-09 アクラリス セラピューティクス，インコーポレイテッド ピロロピリミジンｉｔｋ阻害剤
WO2020132384A1 (en) 2018-12-21 2020-06-25 Celgene Corporation Thienopyridine inhibitors of ripk2
US20220185816A1 (en) * 2019-03-14 2022-06-16 Shanghai Synergy Pharmaceutical Sciences Co., Ltd Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine
WO2020223728A1 (en) 2019-05-02 2020-11-05 Aclaris Therapeutics, Inc. Substituted pyrrolopyridines as jak inhibitors
US11738026B2 (en) 2019-11-22 2023-08-29 Incyte Corporation Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687402B1 (fr) * 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
US5389509A (en) * 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
US6686374B1 (en) * 1999-08-12 2004-02-03 Nps Allelix Corp. Azaindoles having serotonin receptor affinity
HUP0203895A3 (en) * 1999-12-24 2004-09-28 Aventis Pharma Ltd West Mallin Substituted azaindoles and pharmaceutical compositions containing them and their use
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
SE0202463D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
ATE362932T1 (de) 2007-06-15
WO2004099205A1 (en) 2004-11-18
ES2286634T3 (es) 2007-12-01
SE0301372D0 (sv) 2003-05-09
DE602004006618D1 (de) 2007-07-05
EP1625127A1 (en) 2006-02-15
CN1784403A (zh) 2006-06-07
JP2006525998A (ja) 2006-11-16
EP1625127B1 (en) 2007-05-23
AU2004236146B2 (en) 2007-12-13
CA2523922A1 (en) 2004-11-18
BRPI0410117A (pt) 2006-05-23
US20060287354A1 (en) 2006-12-21
AU2004236146A1 (en) 2004-11-18
DE602004006618T2 (de) 2008-01-31

Similar Documents

Publication Publication Date Title
MXPA05012026A (es) Compuestos de azaindol como inhibidores de cinasa.
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
WO2006050161A3 (en) Therapeutic furopyrimidines and thienopyrimidines
WO2005037198A3 (en) Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
TW200612892A (en) Novel compounds
MY154898A (en) P70 s6 kinase inhibitors
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
IL175512A0 (en) Methods of preparing aripiprazole crystalline forms
MY151455A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
EA201290147A1 (ru) Пирроло[2,3-d]пиримидиновые соединения
WO2004092135A3 (en) Substituted benzosulphonamide as potentiators of glutamate receptors
MX2008001538A (es) Aril piridinas y metodos para su uso.
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
TW200609221A (en) 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases
WO2004106322A3 (en) Polymorphs of aripiprazole
RS20050811A (en) Imidazopyridine intermediates
UA92047C2 (uk) Карбоніламінопіролпіразоли - потужні інгібітори кінази
UA88794C2 (en) Pyrrolopyrazoles, potent kinase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration